Chabalgoity José A
Laboratory for Vaccine Research, Department of Biotechnology, Institute of Hygiene, School of Medicine, Uruguay.
Expert Rev Vaccines. 2005 Apr;4(2):147-50. doi: 10.1586/14760584.4.2.147.
The great advances in vaccine R&D over the last 20 years have not been paralleled by the regular introduction of new vaccines into the market thus far. This situation acquires more dramatic proportions in developing countries, where preventable infectious diseases still impose a major public health problem. Furthermore, most of the new developments are being conceived to target the market of industrialized countries and it is foreseeable that their introduction in low-to-middle income countries will be difficult if at any time possible. Strengthening their own capacities for R&D and production is likely to be the most reasonable avenue to ensure that new vaccines will become a sustainable reality for developing countries. Concerted efforts that draw together local capacities (industry and academy) with the experience of large global manufacturers, could have a major impact and provide a great example of an effective partnership to achieve this.
在过去20年里，疫苗研发取得了巨大进展，但迄今为止，新疫苗却未能定期推向市场。这种情况在发展中国家更为严峻，在这些国家，可预防的传染病仍然是一个重大的公共卫生问题。此外，大多数新研发的疫苗都是针对工业化国家市场设计的，可以预见，它们在低收入和中等收入国家的推广即便有可能，也会面临困难。加强自身的研发和生产能力，可能是确保新疫苗成为发展中国家可持续现实的最合理途径。将当地能力（企业和学术机构）与全球大型制造商的经验结合起来的协同努力，可能会产生重大影响，并为实现这一目标提供有效伙伴关系的绝佳范例。
